Benchmark analyst Bruce Jackson reiterated a Hold rating on VolitionRX (NYSE: VNRX).The analyst commented, "VolitionRx is working to monetize its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE